Enhanced Bacillus Calmette-Guerin (BCG) and Antigen Presenting Cells for Bladder Cancer Treatment

The inventive concept disclosed herein relates to novel improvements and enhancements to the original Bacillus Calmette-Guerin (BCG) and antigen presenting cells composition for treating bladder cancer, focusing on direct improvements and enhancements to make the original inventive concept better, faster, safer, or more efficient.

The original patent disclosed the use of BCG and antigen presenting cells for treating bladder cancer. However, the original composition had limitations, such as limited efficacy in elderly patients, lack of personalized treatment options, and limited immune response monitoring capabilities. The new inventive concept addresses these limitations by introducing novel formulations, devices, and methods that enhance the immune response, provide personalized treatment options, and enable effective immune response monitoring.

The new inventive concept comprises five key aspects: (1) a method for treating bladder cancer in elderly patients by administering a vaccine composition with enhanced immune response; (2) a system for personalized bladder cancer treatment using a device for isolating antigen presenting cells and a processor for determining optimal IL-15:IL-15Rα fusion protein complex dosage; (3) a vaccine composition with genetically modified antigen presenting cells expressing a bladder cancer-specific antigen; (4) a method for monitoring immune response to bladder cancer treatment by analyzing urine samples or bladder mucosa for immune cell activation markers; and (5) a kit for preparing a vaccine composition with an instruction manual for formulating the vaccine composition with an IL-15:IL-15Rα fusion protein complex. These aspects work together to provide a more effective, personalized, and efficient treatment for bladder cancer.

The new inventive concept is novel and non-obvious compared to the original patent, as it introduces new formulations, devices, and methods that address the limitations of the original composition. The inventive step lies in the combination of these new aspects, which provide a more comprehensive and effective treatment for bladder cancer.

Alternative embodiments of the inventive concept could include using different types of antigen presenting cells, modifying the IL-15:IL-15Rα fusion protein complex, or incorporating additional immune response enhancers. Variations of the system for personalized treatment could include using different devices or processors for determining optimal dosage.

The new inventive concept has significant commercial potential in the bladder cancer treatment market, which is expected to grow significantly in the coming years. The inventive concept's focus on personalized treatment, enhanced immune response, and effective immune response monitoring makes it an attractive solution for patients, clinicians, and pharmaceutical companies.